Sun Pharma To Buy Organon In $11.75 Billion Acquisition

Indian drugmaker Sun Pharma said it will buy U.S. pharmaceutical company Organon in an all-cash deal valued at $11.75 billion, a major cross-border acquisition that would expand Sun Pharma’s footprint in the United States.

The transaction, announced in recent reports by CNBC and Reuters, values Organon at nearly $12 billion. Sun Pharma and Organon have been described as reaching an agreement for the purchase, with the price set at $11.75 billion and the consideration to be paid entirely in cash.

Sun Pharma is one of India’s largest drugmakers, with a business that has been closely associated with generics as well as a growing portfolio of specialty medicines. Organon is a U.S.-based firm that is publicly listed and operates a portfolio that includes established brands and other pharmaceutical products. The companies were identified in multiple reports as Sun Pharma, the acquirer, and Organon, the target.

The deal stands out for its size and for what it signals about Sun Pharma’s ambitions beyond its home market. At $11.75 billion, it ranks among the most significant acquisitions involving an Indian pharmaceutical company and a U.S. counterpart in recent years, underscoring the strategic importance of the U.S. market for global drugmakers.

For Sun Pharma, acquiring Organon would bring additional scale in the United States, one of the world’s largest and most competitive pharmaceutical markets. The combination would also represent a notable step in Sun Pharma’s effort to broaden its global operations, moving beyond a traditional reliance on generics toward a wider international platform.

For Organon, the agreement sets a clear path toward a change in ownership following its period as a stand-alone public company. In deals of this magnitude, investors typically focus on the purchase price, the expected timeline to close, and any conditions that must be met before the transaction can be completed.

The next steps will center on the formal process required to finalize a transaction of this size. That includes customary regulatory and corporate approvals and the completion of transaction documentation and closing conditions outlined by the companies. Sun Pharma and Organon will also be expected to provide additional details on timing and any other requirements tied to closing.

Until the deal is completed, both companies are expected to continue operating as separate entities while they work through the remaining steps. The announcement marks a decisive move by Sun Pharma to expand its U.S. presence through a marquee acquisition that could reshape its global standing in the pharmaceutical industry.